 Business Today [1] |
Biocon, Pfizer End Pact On Biosimilar Insulin Products [2]
Wall Street Journal Biocon, India's biggest biotechnology company by revenue, is developing biosimilars for treating diseases like diabetes and cancer. It had sold Pfizer exclusive rights to sell recombinant human insulin, glargine, aspart and lispro diabetes–treatment … Is the Pfizer-Biocon deal coming apart? [3]Daily News & Analysis Pfizer scraps insulin deal with India's Biocon [4]Reuters Pfizer terminates $350-mn insulin marketing deal with Biocon [5]domain-B all 253 news articles » [6] |
More details can be found at www.diabeteshowto.com [7]